{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:28:40Z","timestamp":1786991320009,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:00Z","timestamp":1599264000000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jaip.2019.03.039","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T02:32:36Z","timestamp":1554431556000},"page":"2387-2395.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS"],"prefix":"10.1016","volume":"7","author":[{"given":"Richard","family":"Lemal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillemette","family":"Fouquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Terriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Vaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Bulai","family":"Livideanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Barete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Canioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Lhermitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2019.03.039_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.03.039_bib2","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jaci.2006.04.015","article-title":"Molecular regulation of mast cell activation","volume":"117","author":"Rivera","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.039_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nri2327","article-title":"Immunomodulatory mast cells: negative, as well as positive, regulators of immunity","volume":"8","author":"Galli","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaip.2019.03.039_bib4","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaip.2019.03.039_bib5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.03.039_bib6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.iac.2014.01.012","article-title":"Treatment strategies in mastocytosis","volume":"34","author":"Siebenhaar","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2019.03.039_bib7","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.03.039_bib8","doi-asserted-by":"crossref","first-page":"e2266","DOI":"10.1371\/journal.pone.0002266","article-title":"Case-control cohort study of patients' perceptions of disability in mastocytosis","volume":"3","author":"Hermine","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2019.03.039_bib9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.03.039_bib10","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.4049\/jimmunol.1601476","article-title":"From IgE to omalizumab","volume":"197","author":"Kawakami","year":"2016","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2019.03.039_bib11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.03.039_bib12","doi-asserted-by":"crossref","first-page":"903541","DOI":"10.1155\/2015\/903541","article-title":"Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab","volume":"2015","author":"Lieberoth","year":"2015","journal-title":"Case Rep Med"},{"key":"10.1016\/j.jaip.2019.03.039_bib13","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.039_bib14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2340\/00015555-1687","article-title":"Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis","volume":"94","author":"Kibsgaard","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2019.03.039_bib15","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1398-9995.2009.02259.x","article-title":"Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient","volume":"65","author":"Douglass","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.03.039_bib16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2169\/internalmedicine.50.4640","article-title":"Omalizumab treatment of systemic mast cell activation disease: experiences from four cases","volume":"50","author":"Molderings","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.jaip.2019.03.039_bib17","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1398-9995.2009.02045.x","article-title":"Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis","volume":"64","author":"Kontou-Fili","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.03.039_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2007.05.011","article-title":"Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy","volume":"120","author":"Siebenhaar","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.039_bib19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2010.05.043","article-title":"Successful treatment of idiopathic anaphylaxis in an adolescent","volume":"126","author":"Pitt","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.039_bib20","first-page":"563","article-title":"Unpredicted adverse reaction to omalizumab","volume":"21","author":"Jandus","year":"2011","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.039_bib21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.03.039_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jbi.2018.02.019","article-title":"A\u00a0clinician friendly data warehouse oriented toward narrative reports: Dr. Warehouse","volume":"80","author":"Garcelon","year":"2018","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.jaip.2019.03.039_bib23","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.03.039_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2019.03.039_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jim.2005.06.008","article-title":"Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy","volume":"303","author":"Hamilton","year":"2005","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.jaip.2019.03.039_bib26","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.7150\/thno.18304","article-title":"Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcepsilonRI-positive cells in the skin","volume":"7","author":"Metz","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.jaip.2019.03.039_bib27","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(epsilon)RI expression on human basophils during in\u00a0vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2019.03.039_bib28","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.4049\/jimmunol.162.9.5624","article-title":"Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in\u00a0vitro and in\u00a0vivo","volume":"162","author":"Saini","year":"1999","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2019.03.039_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaut.2013.04.005","article-title":"B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome","volume":"51","author":"Nezos","year":"2014","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaip.2019.03.039_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.7754\/Clin.Lab.2014.140618","article-title":"Monitoring of omalizumab therapy by measuring free IgE using a bedside immunoassay","volume":"61","author":"Steiss","year":"2015","journal-title":"Clin Lab"},{"key":"10.1016\/j.jaip.2019.03.039_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.039_bib32","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A\u00a0randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria","volume":"128","author":"Saini","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.039_bib33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaci.2014.04.036","article-title":"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria","volume":"135","author":"Chang","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819303228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819303228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:19:29Z","timestamp":1761974369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219819303228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2213219819303228"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2019.03.039","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2019.03.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}